{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:45:28Z","timestamp":1782726328817,"version":"3.54.5"},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T00:00:00Z","timestamp":1782691200000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-026-00490-2","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:24:17Z","timestamp":1777728257000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiotoxicity of monoclonal antibody-based therapies in breast cancer: a contemporary narrative review"],"prefix":"10.1186","volume":"12","author":[{"given":"Ana Cl\u00e1udia Aparecida","family":"Santos Nussbaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo","family":"Antonini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Mattar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Bacal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Monte Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"11","key":"490_CR1","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1016\/j.cjco.2021.06.019","volume":"3","author":"MM Alhussein","year":"2021","unstructured":"Alhussein MM, Mokbel A, Cosman T, Aghel N, Yang EH, Mukherjee SD, et al. Pertuzumab cardiotoxicity in patients with HER2-positive cancer: a systematic review and meta-analysis. CJC Open. 2021;3(11):1372\u201382.","journal-title":"CJC Open"},{"issue":"3","key":"490_CR2","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"MJ Ahn","year":"2025","unstructured":"Ahn MJ, Tanaka K, Paz-Ares L, Cornelissen R, Girard N, Pons-Tostivint E, TROPION-Lung01 Trial Investigators. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. 2025;43(3):260\u201372.","journal-title":"J Clin Oncol"},{"issue":"3","key":"490_CR3","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1200\/JCO.24.00920","volume":"43","author":"A Bardia","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, TROPION-Breast01 Investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor\u2013positive human epidermal growth factor receptor 2\u2013negative breast cancer: primary results from TROPION-Breast01. Journal of Clinical Oncology. 2025;43(3):285\u201396.","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"490_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/eurjpc\/zwaf026","volume":"33","author":"U Bhalraam","year":"2025","unstructured":"Bhalraam U, Veerni RB, Paddock S, Meng J, Piepoli M, L\u00f3pez-Fern\u00e1ndez T, Vassiliou VS. Impact of sodium\u2013glucose cotransporter-2 inhibitors on heart failure outcomes in cancer patients and survivors: a systematic review and meta-analysis. Eur J Prev Cardiol. 2025;33(2):214\u201326.","journal-title":"Eur J Prev Cardiol"},{"issue":"3","key":"490_CR5","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"490_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-024-12506-0","volume":"24","author":"F Canino","year":"2024","unstructured":"Canino F, Barbolini M, De Giorgi U, Fontana T, Gaspari V, Gianni C, et al. Safety and efficacy analysis of neoadjuvant pertuzumab, trastuzumab and standard chemotherapy for HER2\u2013positive early breast cancer: real\u2013world data from NeoPowER study. BMC Cancer. 2024;24(1):735.","journal-title":"BMC Cancer"},{"issue":"2","key":"490_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1093\/annonc\/mds328","volume":"24","author":"M Capelan","year":"2013","unstructured":"Capelan M, Pugliano L, De Azambuja E, Bozovic I, Saini KS, Sotiriou C, Piccart-Gebhart MJ. Pertuzumab: new hope for patients with HER2-positive breast cancer. Ann Oncol. 2013;24(2):273\u201382.","journal-title":"Ann Oncol."},{"issue":"25","key":"490_CR8","doi-asserted-by":"publisher","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","volume":"28","author":"D Cardinale","year":"2010","unstructured":"Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, Cipolla CM. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28(25):3910\u20136.","journal-title":"J Clin Oncol"},{"issue":"5","key":"490_CR9","doi-asserted-by":"publisher","first-page":"e70174","DOI":"10.1111\/echo.70174","volume":"42","author":"EF Carrizales-Sep\u00falveda","year":"2025","unstructured":"Carrizales-Sep\u00falveda EF, Hern\u00e1ndez-Rangel E, Ordaz-Far\u00edas A. A deeper dive into the myocardium for the detection of cancer therapy-related cardiac dysfunction: radiomics in cardio-oncology. Echocardiography (Mount Kisco, NY). 2025;42(5):e70174.","journal-title":"Echocardiography (Mount Kisco, NY)"},{"issue":"8","key":"490_CR10","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","volume":"30","author":"J Cort\u00e9s","year":"2024","unstructured":"Cort\u00e9s J, Hurvitz SA, Im SA, Iwata H, Curigliano G, Kim SB, Hamilton E. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med. 2024;30(8):2208\u201315.","journal-title":"Nat Med"},{"issue":"12","key":"490_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386(12):1143\u201354.","journal-title":"N Engl J Med"},{"issue":"2","key":"490_CR12","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","volume":"31","author":"G Curigliano","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, Ganatra S, Barac A, Blaes A, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020;31(2):171\u201390.","journal-title":"Ann Oncol"},{"issue":"2","key":"490_CR13","first-page":"159","volume":"6","author":"M Dabour","year":"2024","unstructured":"Dabour M, George MY, Daniel MR, Blaes AH, Zordoky BN. The cardioprotective and anticancer effects of SGLT2 inhibitors. JACC: CardioOncology. 2024;6(2):159\u201382.","journal-title":"JACC: CardioOncology"},{"issue":"1","key":"490_CR14","doi-asserted-by":"publisher","first-page":"100772","DOI":"10.1016\/j.esmoop.2022.100772","volume":"8","author":"E de Azambuja","year":"2023","unstructured":"de Azambuja E, Agostinetto E, Procter M, Eiger D, Pond\u00e9 N, Guillaume S, et al. Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab in early HER2-positive breast cancer in the APHINITY trial. ESMO Open. 2023;8(1):100772.","journal-title":"ESMO Open"},{"issue":"1","key":"490_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/CIRCRESAHA.109.205906","volume":"106","author":"GW De Keulenaer","year":"2010","unstructured":"De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res. 2010;106(1):35\u201346.","journal-title":"Circ Res"},{"issue":"1","key":"490_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s10549-021-06280-x","volume":"188","author":"M Dempsey","year":"2021","unstructured":"Dempsey M, Rosenthal A, Dabas N, Kropotova Y, Lippman M, Bishopric NH. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies. Breast Cancer Res Treat. 2021;188(1):21\u201336.","journal-title":"Breast Cancer Res Treat"},{"key":"490_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2025.115475","volume":"222","author":"N Ding","year":"2025","unstructured":"Ding N, Hermans KE, van Nijnatten E, Engelen SM, Tol J, Kooreman L, et al. Overall survival of patients with de novo HER2-positive metastatic breast cancer in the Netherlands from 2008 to 2017: a population-based cohort study of systemically treated patients. Eur J Cancer. 2025;222:1\u20139.","journal-title":"Eur J Cancer"},{"issue":"24","key":"490_CR18","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.lfs.2013.10.013","volume":"93","author":"AJ Dirks-Naylor","year":"2013","unstructured":"Dirks-Naylor AJ. The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci. 2013;93(24):913\u20136.","journal-title":"Life Sci"},{"key":"490_CR19","doi-asserted-by":"publisher","first-page":"S57","DOI":"10.1093\/annonc\/12.suppl_1.S57","volume":"12","author":"W Eiermann","year":"2001","unstructured":"Eiermann W, International Herceptin Study Group. Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. Ann Oncol. 2001;12:S57\u201362.","journal-title":"Ann Oncol"},{"key":"490_CR20","first-page":"1","volume":"42","author":"M Gion","year":"2022","unstructured":"Gion M, Trapani D, Cort\u00e9s A, Valenza C, Lin N, Cort\u00e9s J, et al. Systemic therapy for HER2-positive metastatic breast cancer: moving into a new era. American Society of Clinical Oncology Educational book. American Society of Clinical Oncology. Annual Meeting. 2022;42:1\u201311.","journal-title":"Annual Meeting"},{"issue":"3","key":"490_CR21","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1056\/NEJMoa2406070","volume":"392","author":"CE Geyer Jr","year":"2025","unstructured":"Geyer CE Jr, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, Loibl S. Survival with trastuzumab emtansine in residual HER2-positive breast cancer. New Engl J Med. 2025;392(3):249\u201357.","journal-title":"New Engl J Med"},{"key":"490_CR22","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, Kumar R. NCCN clinical practice guidelines in oncology - breast cancer- version 4, 2025. NCCN guidelines. 2025."},{"issue":"16","key":"490_CR23","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2217\/fon-2022-1040","volume":"19","author":"WJ Gradishar","year":"2023","unstructured":"Gradishar WJ, O\u2019Regan R, Rimawi MF, Nordstrom JL, Rosales MK, Rugo HS. Margetuximab in HER2-positive metastatic breast cancer. Future Oncol. 2023;19(16):1099\u2013112.","journal-title":"Future Oncol"},{"key":"490_CR24","doi-asserted-by":"publisher","first-page":"660","DOI":"10.54097\/hset.v8i.1253","volume":"8","author":"X Guo","year":"2022","unstructured":"Guo X, Sheng X. Drug discovery of PD-L1 inhibitor Atezolizumab. Highlights Sci Eng Technol. 2022;8:660\u20137.","journal-title":"Highlights Sci Eng Technol"},{"issue":"4","key":"490_CR25","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","volume":"43","author":"J Herrmann","year":"2022","unstructured":"Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Valent P. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. Eur Heart J. 2022;43(4):280\u201399.","journal-title":"Eur Heart J"},{"issue":"1","key":"490_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2014mechanism of action and use in clinical practice. N Engl J Med. 2007;357(1):39\u201351.","journal-title":"N Engl J Med"},{"issue":"44","key":"490_CR27","doi-asserted-by":"publisher","first-page":"e5195","DOI":"10.1097\/MD.0000000000005195","volume":"95","author":"Z Jawa","year":"2016","unstructured":"Jawa Z, Perez RM, Garlie L, Singh M, Qamar R, Khandheria BK, et al. Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Medicine (Baltimore). 2016;95(44):e5195.","journal-title":"Medicine (Baltimore)"},{"key":"490_CR28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.biopha.2017.06.033","volume":"93","author":"AM Kabel","year":"2017","unstructured":"Kabel AM, Elkhoely AA. Targeting proinflammatory cytokines, oxidative stress, TGF-\u03b21 and STAT-3 by rosuvastatin and ubiquinone to ameliorate trastuzumab cardiotoxicity. Biomed Pharmacother. 2017;93:17\u201326.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"490_CR29","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1002\/ejhf.3412","volume":"26","author":"K Keramida","year":"2024","unstructured":"Keramida K, Farmakis D, Rakisheva A, Tocchetti CG, Ameri P, Asteggiano R, Rosano G. The right heart in patients with cancer. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Failure. 2024;26(10):2077\u201393.","journal-title":"Eur J Heart Failure"},{"issue":"4","key":"490_CR30","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1002\/ejhf.1385","volume":"21","author":"K Keramida","year":"2019","unstructured":"Keramida K, Farmakis D, Bingcang J, Sulemane S, Sutherland S, Bingcang RA, et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail. 2019;21(4):529\u201335.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"490_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/ehjcvp\/pvab016","volume":"8","author":"AA Kirkham","year":"2022","unstructured":"Kirkham AA, Pituskin E, Thompson RB, Mackey JR, Koshman SL, Jassal D, et al. Cardiac and cardiometabolic phenotyping of trastuzumab-mediated cardiotoxicity: a secondary analysis of the MANTICORE trial. Eur Heart J Cardiovasc Pharmacother. 2022;8(2):130\u20139.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"5","key":"490_CR32","doi-asserted-by":"publisher","first-page":"100723","DOI":"10.1016\/j.currproblcancer.2021.100723","volume":"45","author":"G Koulaouzidis","year":"2021","unstructured":"Koulaouzidis G, Yung AE, Skonieczna-\u017bydecka K, Marlicz W, Koulaouzidis A, Charisopoulou D. Conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: systematic review and meta-analysis. Curr Probl Cancer. 2021;45(5):100723.","journal-title":"Curr Probl Cancer"},{"issue":"6","key":"490_CR33","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/S1470-2045(17)30313-3","volume":"18","author":"IE Krop","year":"2017","unstructured":"Krop IE, Kim SB, Martin AG, LoRusso PM, Ferrero JM, Badovinac-Crnjevic T, Wildiers H. Trastuzumab emtansine versus treatment of physician\u2019s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743\u201354.","journal-title":"Lancet Oncol"},{"issue":"7","key":"490_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","volume":"15","author":"IE Krop","year":"2014","unstructured":"Krop IE, B KS, Gonz\u00e1lez-Mart\u00edn A, LoRusso PM, Ferrero JM, Schmitt M, et al. Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(7):689\u201399.","journal-title":"Lancet Oncol"},{"issue":"8","key":"490_CR35","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1007\/s00018-019-03340-w","volume":"77","author":"K Leemasawat","year":"2020","unstructured":"Leemasawat K, Phrommintikul A, Chattipakorn SC, Chattipakorn N. Mechanisms and potential interventions associated with the cardiotoxicity of ErbB2-targeted drugs: insights from in vitro, in vivo, and clinical studies in breast cancer patients. Cell Mol Life Sci. 2020;77(8):1571\u201389.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"490_CR36","first-page":"1","volume":"1","author":"DP Leong","year":"2019","unstructured":"Leong DP, Cosman T, Alhussein MM, Kumar Tyagi N, Karampatos S, Barron CC, Dhesy-Thind S. Safety of continuing trastuzumab despite mild cardiotoxicity: a phase I trial. Cardio Oncol. 2019;1(1):1\u201310.","journal-title":"Cardio Oncol"},{"issue":"27","key":"490_CR37","doi-asserted-by":"publisher","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","volume":"43","author":"C Lewinter","year":"2022","unstructured":"Lewinter C, Nielsen TH, Edfors LR, Linde C, Bland JM, LeWinter M, Mansson-Broberg A. A systematic review and meta-analysis of beta-blockers and renin\u2013angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer. Eur Heart J. 2022;43(27):2562\u20139.","journal-title":"Eur Heart J."},{"key":"490_CR38","doi-asserted-by":"publisher","first-page":"821663","DOI":"10.3389\/fcvm.2021.821663","volume":"8","author":"M Lin","year":"2022","unstructured":"Lin M, Xiong W, Wang S, Li Y, Hou C, Li C, et al. The research progress of trastuzumab-induced cardiotoxicity in HER-2-positive breast cancer treatment. Front Cardiovasc Med. 2022;8:821663.","journal-title":"Front Cardiovasc Med"},{"key":"490_CR39","doi-asserted-by":"crossref","unstructured":"Loibl S, Piccart M, Clark E, Viale G, Caballero C, Henry C, Gelber RD. LBA1 Adjuvant pertuzumab or placebo+ trastuzumab+ chemotherapy (P or Pla+ T+ CT) in patients (pts) with early HER2-positive operable breast cancer in APHINITY: Final analysis at 11.3 years\u2019 median follow-up. ESMO Open. 2025;10.","DOI":"10.1016\/j.esmoop.2025.105112"},{"issue":"1","key":"490_CR40","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1186\/s12885-022-09437-z","volume":"22","author":"M Lunardi","year":"2022","unstructured":"Lunardi M, Al-Habbaa A, Abdelshafy M, Davey MG, Elkoumy A, Ganly S, et al. Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review. BMC Cancer. 2022;22(1):396.","journal-title":"BMC Cancer"},{"issue":"3","key":"490_CR41","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1007\/s10549-019-05191-2","volume":"175","author":"F Lynce","year":"2019","unstructured":"Lynce F, Barac A, Geng X, Dang C, Yu AF, Smith KL, Swain SM. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. Breast Cancer Res Treat. 2019;175(3):595\u2013603.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"490_CR42","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, Lopez-Fernandez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, Van Der Pal HJ. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC). Euro Heart J Cardiovasc Imaging. 2022;23(10):e333\u2013465.","journal-title":"Euro Heart J Cardiovasc Imaging"},{"issue":"1","key":"490_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s11739-015-1362-x","volume":"11","author":"S Mantarro","year":"2016","unstructured":"Mantarro S, Rossi M, Bonifazi M, D\u2019Amico R, Blandizzi C, La Vecchia C, et al. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer. Intern Emerg Med. 2016;11(1):123\u201340.","journal-title":"Intern Emerg Med"},{"issue":"4","key":"490_CR44","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s10554-021-02470-2","volume":"38","author":"G Mazzutti","year":"2022","unstructured":"Mazzutti G, Pivatto Junior F, Costa GOM, Foppa M, Biolo A, Santos ABS. Right ventricular function during trastuzumab therapy for breast cancer. Int J Cardiovasc Imaging. 2022;38(4):779\u201387.","journal-title":"Int J Cardiovasc Imaging"},{"issue":"2","key":"490_CR45","doi-asserted-by":"publisher","first-page":"457","DOI":"10.3390\/antiox12020457","volume":"12","author":"G Mendez-Valdes","year":"2023","unstructured":"Mendez-Valdes G, G\u00f3mez-Hevia F, Bragato MC, Lillo-Moya J, Rojas-Sol\u00e9 C, Saso L, et al. Antioxidant protection against Trastuzumab cardiotoxicity in breast cancer therapy. Antioxidants. 2023;12(2):457.","journal-title":"Antioxidants"},{"issue":"5","key":"490_CR46","first-page":"363","volume":"69","author":"KD Miller","year":"2019","unstructured":"Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019;69(5):363\u201385.","journal-title":"CA Cancer J Clin."},{"issue":"6","key":"490_CR47","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.cardfail.2016.04.009","volume":"22","author":"RB Mukku","year":"2016","unstructured":"Mukku RB, Fonarow GC, Watson KE, Ajijola OA, Depasquale EC, Nsair A, et al. Heart failure therapies for end-stage chemotherapy\u2013induced cardiomyopathy. J Card Fail. 2016;22(6):439\u201348.","journal-title":"J Card Fail"},{"issue":"Suppl 6","key":"490_CR48","first-page":"A1","volume":"105","author":"R Nadarajah","year":"2019","unstructured":"Nadarajah R, Koulaouzidis G, Charisopoulou D, Yung D. 86 conventional cardiac risk factors associated with trastuzumab-induced cardiotoxicity in breast cancer: a meta-analysis. Heart. 2019;105(Suppl 6):A1\u2013193.","journal-title":"Heart"},{"issue":"29","key":"490_CR49","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1200\/JCO.22.00369","volume":"40","author":"AR Naqash","year":"2022","unstructured":"Naqash AR, Moey MY, Cherie Tan XW, Laharwal M, Hill V, Moka N, et al. Major adverse cardiac events with immune checkpoint inhibitors: a pooled analysis of trials sponsored by the National Cancer Institute\u2014Cancer Therapy Evaluation Program. J Clin Oncol. 2022;40(29):3439\u201352.","journal-title":"J Clin Oncol"},{"issue":"7","key":"490_CR50","first-page":"2175","volume":"22","author":"MA Nicolazzi","year":"2018","unstructured":"Nicolazzi MA, Carnicelli A, Fuorlo M, Scaldaferri A, Masetti R, Landolfi R, Favuzzi AMR. Anthracycline and trastuzumab-induced cardiotoxicity in breast cancer. Eur Rev Med Pharmacol Sci. 2018;22(7):2175\u201385.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"1","key":"490_CR51","doi-asserted-by":"publisher","first-page":"e003777","DOI":"10.1136\/jitc-2021-003777","volume":"10","author":"A Oaknin","year":"2022","unstructured":"Oaknin A, Gilbert L, Tinker AV, Brown J, Mathews C, Press J, Pothuri B. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient\/microsatellite instability-high (dMMR\/MSI-H) or proficient\/stable (MMRp\/MSS) endometrial cancer: interim results from GARNET\u2014a phase I, single-arm study. J Immunother Cancer. 2022;10(1):e003777.","journal-title":"J Immunother Cancer"},{"issue":"10","key":"490_CR52","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1007\/s00392-019-01448-4","volume":"108","author":"K Ohtani","year":"2019","unstructured":"Ohtani K, Ide T, Hiasa KI, Sakamoto I, Yamashita N, Kubo M, et al. Cardioprotective effect of renin\u2013angiotensin inhibitors and \u03b2-blockers in trastuzumab-related cardiotoxicity. Clin Res Cardiol. 2019;108(10):1128\u201339.","journal-title":"Clin Res Cardiol"},{"issue":"2","key":"490_CR53","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1200\/JCO.2016.67.4887","volume":"35","author":"EA Perez","year":"2017","unstructured":"Perez EA, Eiermann W, Toi M, Im YH, Conte P, Ellis P. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2\u2013positive, advanced breast cancer: primary results from the phase III MARIANNE study. J Clin Oncol. 2017;35(2):141\u20138.","journal-title":"J Clin Oncol"},{"issue":"12","key":"490_CR54","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.repc.2022.10.016","volume":"42","author":"J Pinho","year":"2023","unstructured":"Pinho J, Carvalho M, Paiva M, Teixeira-Tavares N, Costa-Santos C, Sousa C. Is dyslipidemia a risk factor for trastuzumab-induced cardiotoxicity in breast cancer patients? A systematic review and meta-analysis. Rev Port Cardiol. 2023;42(12):961\u201384.","journal-title":"Rev Port Cardiol"},{"issue":"8","key":"490_CR55","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, Jassal D, Pitz M, Haykowsky MJ, Paterson DI. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101\u2013Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35(8):870\u20137.","journal-title":"J Clin Oncol"},{"key":"490_CR56","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","volume":"126","author":"N Pond\u00e9","year":"2020","unstructured":"Pond\u00e9 N, Ameye L, Lambertini M, Paesmans M, Piccart M, de Azambuja E. Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: pooled analysis in advanced HER2-positive breast cancer. Eur J Cancer. 2020;126:65\u201373.","journal-title":"Eur J Cancer"},{"issue":"3","key":"490_CR57","first-page":"302","volume":"4","author":"C Porter","year":"2022","unstructured":"Porter C, Azam TU, Mohananey D, Kumar R, Chu J, Lenihan D, Okwuosa T. Permissive cardiotoxicity: the clinical crucible of cardio-oncology. Cardio Oncol. 2022;4(3):302\u201312.","journal-title":"Cardio Oncol"},{"issue":"11","key":"490_CR58","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/ejhf.2017","volume":"22","author":"R Pudil","year":"2020","unstructured":"Pudil R, Mueller C, \u010celutkien\u0117 J, Henriksen PA, Lenihan D, Dent S, Lyon AR. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Failure. 2020;22(11):1966\u201383.","journal-title":"Eur J Heart Failure"},{"issue":"16","key":"490_CR59","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa052122","volume":"353","author":"EH Romond","year":"2005","unstructured":"Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med. 2005;353(16):1673\u201384.","journal-title":"New Engl J Med"},{"issue":"12","key":"490_CR60","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1038\/s41591-022-02126-1","volume":"28","author":"AH R\u00f8ssevold","year":"2022","unstructured":"R\u00f8ssevold AH, Andresen NK, Bjerre CA, Gilje B, Jakobsen EH, Raj SX, Kyte JA. Atezolizumab plus anthracycline-based chemotherapy in metastatic triple-negative breast cancer: the randomized, double-blind phase 2b ALICE trial. Nat Med. 2022;28(12):2573\u201383.","journal-title":"Nat Med"},{"issue":"2","key":"490_CR61","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1200\/JCO.21.02937","volume":"41","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Im SA, Cardoso F, Cort\u00e9s J, Curigliano G, Musolino A, et al. Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial. J Clin Oncol. 2023;41(2):198\u2013205.","journal-title":"J Clin Oncol"},{"issue":"4","key":"490_CR62","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1001\/jamaoncol.2020.7932","volume":"7","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Im SA, Cardoso F, Cort\u00e9s J, Schneeweiss A, ., et al. Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol. 2021;7(4):573\u201384.","journal-title":"JAMA Oncol"},{"issue":"21","key":"490_CR63","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","volume":"391","author":"P Schmid","year":"2024","unstructured":"Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, K\u00fcmmel S, O\u2019Shaughnessy J. Overall survival with pembrolizumab in early-stage triple-negative breast cancer. New Engl J Med. 2024;391(21):1981\u201391.","journal-title":"New Engl J Med"},{"issue":"9","key":"490_CR64","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278\u201384.","journal-title":"Ann Oncol"},{"issue":"21","key":"490_CR65","doi-asserted-by":"publisher","first-page":"5350","DOI":"10.3390\/cancers13215350","volume":"13","author":"H Shaath","year":"2021","unstructured":"Shaath H, Elango R, Alajez NM. Molecular classification of breast cancer utilizing long non-coding RNA (lncRNA) transcriptomes identifies novel diagnostic lncRNA panel for triple-negative breast cancer. Cancers. 2021;13(21):5350.","journal-title":"Cancers"},{"issue":"1","key":"490_CR66","doi-asserted-by":"publisher","first-page":"e91","DOI":"10.15190\/d.2019.4","volume":"7","author":"GR Soare","year":"2019","unstructured":"Soare GR, Soare CA. Immunotherapy for breast cancer: first FDA approved regimen. Discoveries (Craiova). 2019;7(1):e91.","journal-title":"Discoveries (Craiova)"},{"issue":"4","key":"490_CR67","doi-asserted-by":"publisher","first-page":"101613","DOI":"10.1016\/j.esmoop.2023.101613","volume":"8","author":"LR Soares","year":"2023","unstructured":"Soares LR, Vilbert M, Rosa VDL, Oliveira JL, Deus MM, Freitas-Junior R. Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis. ESMO Open. 2023;8(4):101613.","journal-title":"ESMO Open"},{"issue":"8","key":"490_CR68","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1056\/NEJMoa1413513","volume":"372","author":"SM Swain","year":"2015","unstructured":"Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med. 2015;372(8):724\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"490_CR69","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1634\/theoncologist.2012-0448","volume":"18","author":"SM Swain","year":"2013","unstructured":"Swain SM, Ewer MS, Cort\u00e9s J, Amadori D, Miles D, Knott A, et al. Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2\u2010positive metastatic breast cancer in CLEOPATRA: a randomized, double\u2010blind, placebo\u2010controlled phase III study. Oncologist. 2013;18(3):257\u201364.","journal-title":"Oncologist"},{"issue":"4","key":"490_CR70","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(19)30863-0","volume":"21","author":"SM Swain","year":"2020","unstructured":"Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(4):519\u201330.","journal-title":"Lancet Oncol"},{"issue":"10","key":"490_CR71","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1002\/ejhf.3340","volume":"26","author":"CG Tocchetti","year":"2024","unstructured":"Tocchetti CG, Farmakis D, Koop Y, Andres MS, Couch LS, Formisano L, et al. Cardiovascular toxicities of immune therapies for cancer\u2013a scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology. Eur J Heart Fail. 2024;26(10):2055\u201376.","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"490_CR72","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1093\/jnci\/djae135","volume":"116","author":"E Tonorezos","year":"2024","unstructured":"Tonorezos E, Devasia T, Mariotto AB, Mollica MA, Gallicchio L, Green P, de Moor JS. Prevalence of cancer survivors in the United States. JNCI: Journal of the National Cancer Institute. 2024;116(11):1784\u201390.","journal-title":"JNCI: Journal of the National Cancer Institute"},{"issue":"5","key":"490_CR73","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/sj.bjc.6604940","volume":"100","author":"SM Tovey","year":"2009","unstructured":"Tovey SM, Brown S, Doughty JC, Mallon EA, Cooke TG, Edwards J. Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours. Br J Cancer. 2009;100(5):680\u20133.","journal-title":"Br J Cancer"},{"key":"490_CR74","doi-asserted-by":"publisher","first-page":"115686","DOI":"10.1016\/j.biopha.2023.115686","volume":"168","author":"Z Vaziri","year":"2023","unstructured":"Vaziri Z, Saleki K, Aram C, Alijanizadeh P, Pourahmad R, Azadmehr A, et al. Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications. Biomed Pharmacother. 2023;168:115686.","journal-title":"Biomed Pharmacother"},{"issue":"19","key":"490_CR75","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Gianni L, Krop IE, Welslau M, Baselga J, Blackwell K. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783\u201391.","journal-title":"N Engl J Med"},{"issue":"7","key":"490_CR76","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G Von Minckwitz","year":"2019","unstructured":"Von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380(7):617\u201328.","journal-title":"N Engl J Med"},{"issue":"26","key":"490_CR77","doi-asserted-by":"publisher","first-page":"e15872","DOI":"10.1097\/MD.0000000000015872","volume":"98","author":"J Wang","year":"2019","unstructured":"Wang J, Xu R, Yuan H, Zhang Y, Cheng S. Single-cell RNA sequencing reveals novel gene expression signatures of trastuzumab treatment in HER2+ breast cancer: a pilot study. Medicine (Baltimore). 2019;98(26):e15872.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"490_CR78","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-022-01294-4","volume":"15","author":"J Weng","year":"2022","unstructured":"Weng J, Li S, Zhu Z, Liu Q, Zhang R, Yang Y, et al. Exploring immunotherapy in colorectal cancer. J Hematol Oncol. 2022;15(1):95.","journal-title":"J Hematol Oncol"},{"key":"490_CR79","unstructured":"Wild CP, Weiderpass E, Stewart B, World Health Organization. World cancer report. 2020."},{"issue":"4","key":"490_CR80","doi-asserted-by":"publisher","first-page":"e70136","DOI":"10.1111\/echo.70136","volume":"42","author":"C Xia","year":"2025","unstructured":"Xia C, Wu S, Zhong Y, Wang J, Yao A, Liu B. Clinical study of post-chemotherapy cardiotoxicity in breast cancer patients based on ultrasound radiomics. Echocardiography (Mt Kisco NY). 2025;42(4):e70136.","journal-title":"Echocardiography (Mt Kisco NY)"},{"issue":"1","key":"490_CR81","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1200\/OP.23.00494","volume":"20","author":"P Zagami","year":"2024","unstructured":"Zagami P, Trapani D, Nicol\u00f2 E, Corti C, Valenza C, Criscitiello C, et al. Cardiotoxicity of agents used in patients with breast cancer. JCO Oncology Practice. 2024;20(1):38\u201346.","journal-title":"JCO Oncology Practice"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-026-00490-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00490-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-026-00490-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T09:04:46Z","timestamp":1782723886000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40959-026-00490-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":81,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["490"],"URL":"https:\/\/doi.org\/10.1186\/s40959-026-00490-2","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"82"}}